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Competition between normal [674C] and mutant [674R]GPIIb subunits: role of
the molecular chaperone BiP in the processing of GPIIb-IIIa complexes
Elena G. Arias-Salgado, Nora Butta, Consuelo Gonza´lez-Mancho´n, Susana Larrucea, Matilde S. Ayuso, and Roberto Parrilla
This work aimed at investigating the func-
tion of the [C674R] mutation in GPIIb that
disrupts the intramolecular 674 to 687
disulfide bridge. Individuals heterozy-
gous for this mutation show a platelet
GPIIb-IIIa content approximately 30% of
normal controls, which is less than ex-
pected from one normal functioning al-
lele. Coexpression of normal [674C]GPIIb
and mutant [674R]GPIIb with normal
GPIIIa produced a [674R]GPIIb concentra-
tion-dependent inhibition of surface expo-
sure of GPIIb-IIIa complexes in Chinese
hamster ovary (CHO) cells, suggesting
that [674R]GPIIb interferes with the asso-
ciation and/or intracellular trafficking of
normal subunits. Mutation of either 674C
or 687C had similar effects in reducing
the surface exposure of GPIIb-IIIa. How-
ever, substitution of 674C for A produced
a much lesser inhibition than R, suggest-
ing that a positive-charged residue at that
position renders a less efficient subunit
conformation. The mutant [674R]GPIIb but
not normal GPIIb was found associated
with the endoplasmic reticulum chaper-
one BiP in transiently transfected CHO
cells. BiP was also found associated with
[674R]GPIIb-IIIa heterodimers, but not with
normal GPIIIa or normal heterodimers.
Overexpression of BiP did not increase
the surface exposure of [674R]GPIIb-IIIa
complexes, indicating that its availability
was not a limiting step. Platelets from the
thrombasthenic patient expressing [674R]-
GPIIb-IIIa were found to bind soluble fi-
brinogen in response to physiologic ago-
nists or dithiothreitol treatment. Thus, the
[674R]GPIIb mutation leads to a retarda-
tion of the secretory pathway, most likely
related to its binding to the molecular
chaperone BiP, with the result of a defec-
tive number of functional GPIIb-IIIa recep-
tors in the cell surface. (Blood. 2001;97:
2640-2647)
© 2001 by The American Society of Hematology
Introduction
Glanzmann thrombasthenia (GT)1 is a recessively inherited bleed-
ing disorder characterized by appearance of symptoms immedi-
ately after birth, normal platelet count, prolonged bleeding time,
and low to absent clot retraction. A distinct feature of GT is the lack
of platelet aggregation both spontaneously or in response to
physiologic agonists and a normal ristocetin-induced aggregation.
GT is a rather heterogeneous entity,2 but, in all cases studied, the
thrombasthenic phenotype is associated with either a deficient or
defective platelet fibrinogen (Fg) receptor.3,4 GT is currently
classified as type I or type II.5 In type I GT there is absence of
platelet GPIIb-IIIa and Fg and lack of clot retraction; in type II GT
the platelet content may be around 10%, Fg may be detectable, and
weak clot retraction may be observed. The platelet from the
so-called GT variants may contain normal or near normal dysfunc-
tional GPIIb-IIIa complexes.4,6 The calcium-dependent het-
erodimer formed by the glycoproteins GPIIb and GPIIIa, also
known as integrin aIIbb3, is a receptor for Fg and other adhesive
proteins and is the major platelet plasma membrane protein
component. Since the primary nucleotide structure of the human
GPIIb and GPIIIa has become available,7-11 a significant number of
mutations in both GPIIb and GPIIIa have been detected that are
associated with thrombasthenic phenotypes.12,13 We have reported
a compound heterozygote for GPIIb associated with type II GT.14
One of the mutations found in this patient was a splice site
mutation, resulting in insertion of intron 5, appearance of a
premature stop codon, and instability of messenger RNA (mRNA).
The second mutation was a T2113C transition that changes C674R,
disrupting the 674-687 intramolecular disulfide bridge. The plate-
lets from the proband contained only subnormal amounts of
[674R]GPIIb transcript, as expected from the expression of only
one allele, and the platelet content of GPIIb-IIIa was about 10% of
the normal platelets. Even though both parents of the proband
carried one normal functional allele, the platelet GPIIb-IIIa content
was approximately 30% and 50% of the normal platelet control in
the mother and father, respectively. The difference between both
parents is that the father has only transcripts from a normal allele,
whereas the mother transcribes at similar rates normal and mutant
[674R]GPIIb alleles. On the basis of these observations, we
hypothesized that the decreased surface expression of GPIIb-IIIa in
the platelets of the mother could be the result of interference
between the translational products of both normal and mutant
transcripts. This possibility has been investigated by coexpressing
variable proportions of normal and mutant [674R]GPIIb with
normal GPIIIa in Chinese hamster ovary (CHO) cells. The present
work also aimed at elucidating the molecular mechanism respon-
sible for the reduced surface expression of [674R]GPIIb-IIIa
complexes in the proband’s platelets as well as determining the
functionality of the platelet receptor. It has been observed that
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intracellular retention of pro[674R]GPIIb associated with the
chaperone BiP may play a role in determining the reduced surface
exposure of [674R]GPIIb-IIIa. However, platelets from the pro-
band showed normal responsiveness to physiologic agonists,
manifested by enhanced binding of Fg and the activation-
dependent monoclonal antibody (moab) PAC1. According to these
observations, preservation of the 674-687 intramolecular disulfide
bridge is essential to maintain a normal rate of GPIIb and GPIIIa
dimerization and intracellular trafficking but does not compromise
the physiologic responsiveness of the exposed receptor.
Materials and methods
Construction of expression vectors with normal or mutant
GPIIb complementary DNAs
The complementary DNA (cDNA) for the [674R]GPIIb mutant was
prepared by the splicing overlap extension polymerase chain reaction
(PCR) procedure as previously described,15 using 2 sets of oligonucleotide
primers: GPIIb-sense-(955-979) 59-TATTTTGGGCATTCAGTGGCTGTCA-
39, GPIIb-antisense-(2123-2103) 59-TTCTGATTACGGATGAGTCTC-39, GPIIb-
sense-(2103-2123) 59-GAGACTCATCCGTAATCAGAA-39, and GPIIb-anti-
sense-(3154-3133) 59-CACCCTCCTGCTAGAATAGT-39. Bases substituted to
generate the mutation are underlined. The final PCR carrying the mutation was
digested with AccI and BamHI and ligated in a vector containing the wild-type
GPIIb cDNA previously digested with the same enzymes. cDNAs encoding
[674A]GPIIb and [687A]GPIIb mutants were prepared as above, using the
overlapped pairs of primers GPIIb-A674-sense 59-GAGACTCATCGCTAATCA-
GAAGAA-39, GPIIb-A674-antisense 59-TTCTTCTGATTAGCGATGAGTCTC-
39, GPIIb-A687-sense 59-CAGGGTGG TGCTGGCTGAG-39, and GPIIb-A687-
antisense 59-AGCTCAGCCAGCACCACCCT-39, respectively. [674R]GPIIb
and [687A]GPIIb cDNAs were used as templates to generate [674R/687A]GPIIb
and [674A/687A]GPIIb mutant cDNAs, respectively. Nucleotide sequence
analysis was performed to confirm the insertion of the amplified mutant products
into the normal GPIIb and the absence of potential errors introduced by the Taq
polymerase. Normal or mutated cDNAs were subcloned into the HindIII site of
the pcDNA3 expression vector.
Cell culture and transfection
CHO or CHO-GPIIIa (CHO cell line stably expressing GPIIIa) cells were
grown in Dulbecco modified Eagle medium (DMEM) supplemented with
10% fetal calf serum. Cells were transiently cotransfected by the diethyl
aminoethyl-dextran method16 with different amounts of pcDNA3-GPIIIa,
normal and/or mutated pcDNA3-GPIIb constructs, and/or the pMT-BiP
vector. The total amount of DNA transfected was equalized with void
plasmid. To determine the transfection efficiency, 2.5 mg of the pCMV,
b-galactosidase plasmid was cotransfected in some experiments. Forty-
eight hours after transfection, the cells were harvested, and the surface
expression or total content of GPIIb-IIIa complexes was determined
as follows.
Flow cytometry analysis
Transfected cells were harvested, using 0.5 mM EDTA in phosphate-
buffered saline (PBS), washed with PBS, resuspended at a density of 106
cells/100 mL, and incubated for 20 minutes at 4°C with moAbs specific to
GPIIb (M3) or GPIIIa (P37). Next, cells were washed and exposed to
fluorescein isothiocyanate–conjugated (FITC) F(ab9)2 fragment of rabbit
antimouse immunoglobulin (DAKO A/S, Denmark) at 4°C for 20 minutes,
and the surface fluorescence was analyzed in a Coulter flow cytometer,
model EPICS XL.
Immunoprecipitation of GPIIb-IIIa and Western analysis of BiP
Immunoprecipitation of GPIIb-IIIa from CHO cells was performed as
previously described.17,18 Briefly, transfected cells were treated with lysis
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM phenylmethyl sulfonyl
fluoride, 1% Triton X-100, 0.05% Tween 20, and 0.03% sodium azide) for
30 minutes at 4° C, and then precleared lysates were immunoprecipitated
with either moAb M3 or moAb P37. The immunoprecipitates were then
bound to protein A-Sepharose CL-4B beads, washed, and eluted by
incubating 10 minutes at 100°C in 50 mL reducing loading buffer (50 mM
Tris-HCl, pH 6.8, 10% glycerol, 5% b-mercaptoethanol, 4% sodium
dodecyl sulfate [SDS], and 0.002% bromophenol blue). To examine the
association of GPIIb and/or GPIIIa with the chaperone BiP (GRP78),
immunoprecipitates obtained in the presence of 10 U/mL apyrase (Sigma,
St Louis, MO) were electrophoresed in 0.1% SDS-7.5% polyacrylamide
gels and transferred to nitrocellulose membranes. The membrane was
incubated with a polyclonal antibody to rodent BiP and then with a
secondary goat antirabbit immunoglobulin (Ig)G-peroxidase conjugated
(Sigma). The membrane was developed by incubation in PBS containing
0.015% H2O2 and 0.5 mg/mL 4-chloro-1-naphtol.
Pulse-chase analysis of GPIIb-IIIa synthesis
Pulse-chase analysis of CHO cells transfected with wild-GPIIb and/or
[674R]GPIIb was performed 48 hours after transfection. The cells were
incubated in DMEM without methionine for 30 minutes and then pulsed for
30 minutes with [35S]methionine (200 mCi/mL). The plates were washed 3
times with PBS containing 1 mg/mL cold methionine and incubated with
DMEM containing unlabeled methionine for 0, 0.5, and 2 hours. Cells were
washed with PBS containing cold methionine and extracted in lysis buffer.
Immunoprecipitation analysis was performed as described above. The
immunoprecipitates were electrophoresed at 50 V in 0.1% SDS-7.5%
polyacrylamide slab gels. The gels were vacuum dried and exposed to
hypersensitive x-ray film. The immunoreactive bands were digitized with a
high-resolution scanner and analyzed on a Macintosh computer, using the
public domain software NIH Image (http: //rsb.info.nih.gov/nih-image).
Preparation of FITC-Fg
Human Fg was incubated with 10% celite-FITC (Calbiochem, San Diego,
CA) in PBS at room temperature for 60 minutes. The pH was adjusted to 8.5
with 5% Na2CO3. The celite-FITC was separated from the labeled Fg by
centrifugation, and the unreacted free FITC was cleaned from FITC-Fg by
passing through a PD-10 column (Pharmacia, Uppsala, Sweden) in PBS,
pH 7.4, and exhaustive dialysis at 4°C. The fluorescein-to-protein ratio was
determined by measuring absorbance at 495 nm and 280 nm. Aliquots of
FITC-Fg are stored at 280°C and thawed for experiments on a single
day only.
Binding of Fg to activated platelets
Blood was collected in 1/10 volume of 3.8% sodium citrate, and platelet-
rich plasma (PRP) was obtained by centrifugation at 180g for 20 minutes at
room temperature. The PRP was then centrifuged at 800g for 10 minutes,
and the platelet pellet was resuspended in Tyrode buffer, pH 7.4 (5 mM
HEPES, 2 mM MgCl2, 0.3 mM NaH2PO4, 3 mM KCl, 134 mM NaCl, 12
mM NaHCO3, 0.1% glucose, 0.1% bovine serum albumin, and 1 mM
Cl2Ca.) at a final concentration of 4 3 107/mL. Platelets (50 mL) were
stimulated for 5 minutes at room temperature with one or more of the
following activating agents: 20 mM dithiothreitol (DTT) (BRL, Life
Technologies), 20 nmol/L phorbol 12-myristate 13-acetate (PMA) (Sigma),
200 mM adenosine 59-diphosphate (Sigma), 1 mM (2)epinephrine (Sigma),
1.5 U/mL human plasma thrombin (Sigma), 100 mM thrombin receptor
agonist peptide (SFLLRN), 2 mM platelet activating factor-16 (Calbio-
chem). To prevent thrombin-induced fibrin polymerization, GPRP peptide
(Bachem, Bubendorf, Switzerland) was added to the incubation medium.
Next, 15 mg FITC-Fg was added to activated platelets and incubated 15
minutes at room temperature. After washing, the platelets were resuspended
in Tyrode buffer for flow cytometry analysis. We examined also the binding
of FITC-labeled PAC-1, antibody specific for the active conformation of
GPIIb-IIIa, in PMA-treated platelets.
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Materials
Restriction enzymes were obtained from Boehringer (Mannheim, Ger-
many). The pcDNA3 expression vector was from Invitrogen (San Diego,
CA). Most other reagents were purchased from Sigma Chemical Company
(St. Louis, MO), Merck (Darmstadt, Germany), or Calbiochem-Novabio-
chem Corporation (San Diego, CA). [35S]-methionine (SA 1000 Ci/mmol)
was from Amersham Ibe´rica (Madrid, Spain). moAbs specific for GPIIIa
(P37) and GPIIb (M3) were a gift of Drs J. Gonza´lez and M. V. Alvarez
from the Institute Rocasolano (CSIC; Madrid, Spain). Polyclonal antirodent
BiP and pMT/hamster wild BiP cDNA were a generous gift from Dr Linda
Hendershot at St. Jude’s Research Hospital (Memphis, TN). FITC-PAC1
was obtained from Dr J. Lopez (VA Medical Center, Houston, TX).
Results
Pulse-chase analysis of stability of [674R]GPIIb-IIIa complexes
We have reported a case of compound heterozygosity for GPIIb
associated with type II GT.14 The mutation inherited from the father
[IVS5(12)CA] renders the mRNA unstable and, therefore, the only
mRNA-GPIIb found in the platelets of this patient was the one
encoding the mutated [C674R]GPIIb inherited from the mother.
The patient showed very low platelet GPIIb-IIIa content and
elevated ratio of proGPIIb to GPIIbH. Moreover, coexpression of
[674R]GPIIb and GPIIIa in CHO cells led to a marked reduction in
the surface exposure of GPIIb-IIIa complexes. Although the latter
observation indicates that subunit dimerization is not prevented, the
reason for the low rate of surface expression of GPIIb-IIIa is not
apparent. In principle, it could be the result of either instability of
the [674R]GPIIb-IIIa complexes and/or retardation in the intracel-
lular transit along the secretory pathway. To investigate this point,
cells transiently cotransfected with normal GPIIIa and either
mutant [674R]GPIIb or normal GPIIb were pulse-labeled for 30
minutes with [35S]methionine and then chased with medium
containing unlabeled methionine for 0.5 or 2 hours before GPIIb-
IIIa complexes were immunoprecipitated with an anti-GPIIb
moAb. As expected, reciprocal changes in the labeling of pro-
GPIIb, and of GPIIbH and GPIIIa, as a function of the chasing time
were observed in cells coexpressing normal GPIIb and GPIIIa
proteins (Figure 1). This observation implies stability of GPIIb-IIIa
complexes and their transport into the Golgi apparatus. In cells
cotransfected with GPIIIa and mutant [674R]GPIIb, proGPIIb,
GPIIbH, and GPIIIa subunits were coprecipitated with anti-GPIIb
at all times, but the labeling flow was considerably slower than in
cells coexpressing both normal subunits. The decay of labeled
proGPIIb was retarded (Figure 1), suggesting that the number of
subunits entering the secretory pathway may be diminished. After 2
hours of chase, the pattern of labeling of cells expressing [674R]-
GPIIb was similar to that observed in the control cells at zero time.
In CHO cells, the majority (99%) of GPIIb-IIIa is located on the
plasma membrane.19 According to this, in a pulse-chase experiment
the labeling intensities of GPIIb and GPIIIa should be proportional
to the amount of GPIIb-IIIa complexes that have reached the cell
surface. The reduced rate of labeling of [674R]GPIIb-IIIa com-
plexes could be caused by impairment of the association of
[674R]GPIIb with GPIIIa, by retardation of the metabolic flow
along the maturation and trafficking pathway, or by the concurrent
action of both mechanisms. Whatever the mechanism, it seems that
the [674R]GPIIb mutation either changes the kinetics of a preexist-
ing step or imposes a new limiting step to the normal processing
pathway of GPIIb-IIIa complexes.
Association of abnormal GPIIb or GPIIIa subunits with the
endoplasmic reticulum chaperone BiP (GRP78)
The pulse-chase analysis seems to suggest that an early step in the
surface expression pathway of [674R]GPIIb-IIIa may be impaired.
Since the substitution of 674C in GPIIb implies the disruption of an
intramolecular disulfide bridge and subsequent conformational
changes, we found of interest to analyze the interaction of normal
or [674R]GPIIb with the chaperone BiP. For this purpose, total cell
lysates from CHO cells coexpressing GPIIIa and either normal or
mutant [674R]GPIIb, or expressing only normal GPIIb, mutant
[674R]GPIIb, or GPIIIa, were immunoprecipitated with an anti-
GPIIb moAb and the precipitates used for Western analysis using a
polyclonal antibody against the hamster BiP chaperone. Figure 2
indicates that the chaperone BiP was coprecipitated with [674R]-
GPIIb but not with normal GPIIb. To elucidate whether the
immunoprecipitated BiP was associated with mutant monomeric
pro[674R]GPIIb or it was also bound to heterodimers, we per-
formed the same type of analysis precipitating portions of the cell
lysates with an anti-GPIIIa antibody reacting with monodimeric
and heterodimeric GPIIIa. Figure 3 shows that anti-GPIIIa copre-
cipitated BiP only in cells coexpressing [674R]GPIIb and normal
GPIIIa, suggesting that, at least under our experimental conditions,
BiP associated with abnormal conformations of monomeric GPIIb
as well as with mutant heterodimeric complexes. The observation
that BiP immunoprecipitates with a mutant form of GPIIb (E324K)
(Figure 3) unable to form heterodimers with GPIIIa20 clearly
indicates that the BiP binding is independent of the type of GPIIb
mutation and its consequence on assembly; it also indicates that
assembly is not a prerequisite for BiP binding.
Figure 1. Pulse-chase analysis of [674C] and [674R]GPIIb-IIIa synthesis. CHO
cells, transiently transfected with cDNAs encoding GPIIIa and either normal [674C] or
mutant [674R]GPIIb, were pulse-labeled with [35S]methionine for 30 minutes and
then chased with medium containing unlabeled methionine. At the indicated times,
the cells were lysed and immunoprecipitated with anti-GPIIb. The precipitates were
analyzed by electrophoresis as described in “Materials and methods.”
Figure 2. Association of mutant [674R]GPIIb with the endoplasmic reticulum
chaperone BiP. CHO cells were transiently transfected with the indicated cDNAs,
lysed, and immunoprecipitated with the anti-GPIIb moAb M3. The precipitates were
resolved by electrophoresis, transferred to nitrocellulose membrane, and blotted with
polyclonal anti-BiP antibody, as described in “Materials and methods.”
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The apparently high-affinity binding of BiP to mutated [674R]-
GPIIb suggested that availability of BiP could become limiting,
preventing, therefore, the access of new proGPIIb peptides into the
maturation pathway. To investigate this possibility, we cotrans-
fected 2 different amounts of mutant [674R]GPIIb with normal
GPIIIa and BiP expression plasmids. No significant effect of BiP
was detected in the rate of surface expression of [674R]GPIIb-IIIa
complexes (results not shown), making unlikely that it could have
been limiting.
Mutation analysis of the 674 and 687 residues of GPIIb
The 674C of GPIIb forms an intramolecular disulfide bridge with
687C. To ascertain whether the [674R]GPIIb dysfunction was
associated with the loss of the disulfide bridge, or with the specific
need for a C at position 674, we analyzed the functional repercus-
sion of loosing the 674-687 disulfide bridge by changing the Cs 674
or 687 for A. Figure 4 (upper panel) depicts the surface expression
of GPIIb-IIIa in CHO-IIIa cells transfected with normal or mutated
forms of GPIIb. The mutation C674R found in the proband
decreased by approximately 70% the surface expression of trans-
fected GPIIb-IIIa. The C674A or C687A mutations produced
smaller (approximately 40%-50%) inhibitions. The mutation of
either 674C or 687C produced similar inhibition; however, the
additive result of mutating both residues suggests the appearance of
effects unrelated to disulfide disruption (Figure 4). Total cell lysates
from transfected cells were immunoprecipitated with anti-GPIIb,
and the presence of BiP in the precipitates was analyzed by Western
blotting. The results so obtained indicate (Figure 4, bottom) that
BiP was tightly associated not only with natural-occurring muta-
tions of GPIIb but also with mutated forms of GPIIb created in
the laboratory.
Physiologic responsiveness of platelets carrying
the [674R]GPIIb mutation
The reduced level of expression of [674R]GPIIb-IIIa justifies the
thrombasthenic phenotype of the patient. However, we found of
interest from the academic and prognostic standpoints to determine
the ability of the mutated [674R]GPIIb-IIIa complexes to undergo
an activated state in response to stimulation by agonists. Platelets
from the proband and normal individuals were incubated in the
presence of physiologic agonists, DTT, or PMA, and the binding of
soluble FITC-Fg determined by flow cytometric analysis. The
fluorescence of the proband’s platelets was about 10% of the
control values (results not shown). Thus, the enhanced fluorescence
intensity after platelet activation was reasonably proportional to the
number of surface receptors, suggesting that the mutated platelet
[674R]GPIIb-IIIa complexes undergo normal in-out signaling-
mediated conformational changes. This conclusion is also sup-
ported by the enhanced binding of the activation-dependent IgM
PAC1 to the proband’s platelets after PMA-induced postreceptor
stimulation (Figure 5).
Competition between normal and [674R]GPIIb for surface
expression of GPIIb-IIIa complexes
The heterozygous states for the [674R]GPIIb mutation expressed
less than 50% of platelet GPIIb-IIIa of normal individuals. Since
this mutated GPIIb allele yields normal amounts of full-length
transcripts, we hypothesized that a reason for the decreased surface
exposure of GPIIb-IIIa complexes could be a competition between
the translational products of the normal and mutated alleles at some
limiting step(s). To elucidate this point, we cotransfected CHO-IIIa
cells with progressively increasing ratios of normal and/or mutated
GPIIb cDNAs. Figure 6A depicts the surface GPIIb-IIIa content as
Figure 5. PAC1 binding to activated platelets. Platelets from the thrombasthenic
patient and normal controls were incubated with or without PMA (20 nmol/L) for 5
minutes and then incubated with the moAb FITC-PAC1 and analyzed by flow
cytometry.
Figure 3. Coimmunoprecipitation of BiP with [674R]GPIIb-IIIa complex. CHO
cells, transiently cotransfected with cDNAs encoding GPIIIa and either normal
[674C]GPIIb or mutant forms of GPIIb, were immunoprecipitated with the indicated
antibodies. The precipitates were analyzed by electrophoresis, transferred to nitrocel-
lulose membrane, and blotted with polyclonal anti-BiP antibody, as described in
“Materials and methods.”
Figure 4. Effects of substitutions of 674C and 687C of GPIIb in the surface
exposure and BiP association of GPIIb-IIIa complexes. CHO-IIIa cells were
transfected with the cDNA encoding normal [674C]GPIIb or mutant forms of GPIIb, as
indicated. In the upper panel, the surface expression of GPIIb-IIIa complex was
determined by flow cytometry, using an anti-GPIIb moAb. The results are expressed
as a percentage of the surface exposure of normal [674C]GPIIb-IIIa complexes. The
results are the means 6 SEM of at least 3 independent experiments in duplicate. In
the lower panel, immunoprecipitation of the cell lysates and Western blot analysis of
the precipitates were performed as described in “Materials and methods.”
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a function of the amount of transfected expression plasmid(s). This
process shows a saturation-type kinetics, and the maximal value
with the mutated GPIIb plasmid was reached at much lower
concentration than with normal GPIIb. Figure 6B shows the
measured and estimated surface exposure of GPIIb-IIIa in cells
coexpressing molar ratios of normal and mutated GPIIb from 0.2 to
5. In estimating the surface GPIIb-IIIa we assumed, according to
results on panel A (Figure 6), that in this range of plasmid
concentration transfection is not a limiting step and that surface
expression from both cDNAs should be additive. Unexpectedly,
instead of additivity, the results show a progressively increasing
inhibition of surface exposure of normal GPIIb-IIIa complexes as
the normal [674C]GPIIb-to-mutant [674R]GPIIb ratio decreased
from 5 to 0.2 (Figure 6C). It should be remarked that cotransfection
of equimolar amounts (2 mg of each expression plasmid) of normal
and mutant GPIIb, presumably the expected physiologic condition,
inhibited the surface exposure of GPIIb-IIIa by approximately
35%. Moreover, pulse-chase analysis of cells cotransfected with
equimolar amounts of normal and mutant GPIIb clearly shows a
prolonged retention of labeling in proGPIIb and decreased labeling
of GPIIb-IIIa (Figure 7). Densitometric analysis of data shown in
Figure 7 was consistent with that obtained by flow cytometry
(Figure 6). The immunoprecipitation with anti-GPIIIa of heavily
labeled GPIIIa in all conditions (Figure 7, bottom panel) rules out
that availability of GPIIIa could have been limiting for the surface
expression of GPIIb-IIIa.
Since the mutated [674R]GPIIb is bound to BiP, a limited
availability of this chaperone could explain the observed competi-
tion between the normal and mutant forms of GPIIb. We investi-
gated this possibility coexpressing BiP with variable amounts of
normal or mutant GPIIb so that the mutant-to-normal GPIIb ratio
varied from 1 to 3. The data in Figure 8 clearly indicate that
overexpression of BiP did not overcome the inhibitory effects of
the mutant [674R]GPIIb on the surface exposure of the normal
subunit, but, on the contrary, a consistent inhibitory effect was
observed at all mutant-to-normal GPIIb ratios analyzed. Finally,
the possibility should be considered that binding of BiP to
[674R]GPIIb-IIIa complexes would make limiting the availability
of GPIIIa subunits. However, it is unlikely that this mechanism
Figure 7. Pulse-chase analysis of cells cotransfected with GPIIIa and either
normal GPIIb, mutant [674R]GPIIb, or equimolar amounts of both GPIIb cDNAs.
CHO cells, transiently transfected with cDNAs encoding GPIIIa and either normal
[674C]GPIIb, mutant [674R]GPIIb, or equimolar amounts of both cDNAs, were
pulse-labeled with [35S]methionine for 30 minutes and then chased with medium
containing unlabeled methionine. At the indicated times, the cells were lysed and
immunoprecipitated with either anti-GPIIb or anti-GPIIIa. The precipitates were
analyzed by electrophoresis as described in “Materials and methods.”
Figure 8. Overexpression of BiP in CHO-IIIa cells cotransfected with normal
and mutant GPIIb. CHO-IIIa cells were cotransfected with different proportions of
normal and mutant [674R]GPIIb cDNAs, as described in Figure 6, and 4 mg of the BiP
cDNA or the void plasmid. Forty-eight hours after transfection, the surface exposure
of GPIIb-IIIa was analyzed by flow cytometry with the anti-GPIIb moAb M3. The
results are the means 6 SEM of at least 3 independent experiments in duplicate.
Figure 6. Competition of normal and mutant [674R]GPIIb for surface expres-
sion of GPIIb-IIIa complexes. (A) CHO-IIIa cells were transiently transfected with
variable amounts of normal (E) or mutant (F) [674R]GPIIb cDNAs. The surface
exposure of GPIIb-IIIa heterodimers was analyzed by flow cytometry with anti-GPIIb.
The results are the means 6 SEM of at least 3 independent experiments in duplicate.
(B) CHO-IIIa cells were cotransfected with normal to mutant [674R]GPIIb molar ratios
from 0.2 to 5, and the surface expression of GPIIb-IIIa complexes was determined by
flow cytometry (f). At the normal to mutant ratio of 1, 2 mg of each plasmid was
cotransfected. The estimated values (M) were obtained, assuming that, according to
results on panel A, the surface expression from the translational product of both
cDNAs should be additive. (C) The percentage of inhibition of surface exposure of
GPIIb-IIIa was calculated from the differences between the estimated and the
measured values shown in panel B.
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might be quantitatively important in view of the scarce amounts of
mutant heterodimers immunoprecipitated with antibodies capable
of identifying each subunit as either monomer or heterodimer.
Discussion
Role of the 674-687 disulfide bond of GPIIb on the biological
function of the GPIIb-IIIa complex
The C674R GPIIb mutation disrupts the intrachain 674-687
disulfide bond. This mutation has been found in a thrombasthenic
phenotype, heterozygote compound for GPIIb, whose platelet
content of GPIIb-IIIa was about 10% of the normal control
individuals and that only platelet mRNA-GPIIb was the one
encoding [674R]GPIIb. Coexpression of normal GPIIIa and [674R]-
GPIIb in CHO cells confirmed the reduced rate of surface
expression of [674R]GPIIb-IIIa complexes. However, from this
type of experiment it cannot be ascertained whether the loss of the
674-687 disulfide bond impairs the function of the cell surface
receptors. The platelets from the proband respond to a battery of
activating agents by increasing the binding of soluble Fg with
intensity proportional to the number of exposed receptors. This
observation clearly indicates that loss of the 647-687 intrachain
disulfide bond does not compromise the agonist-mediated respon-
siveness of the exposed [674R]GPIIb-IIIa complexes. Thus, consid-
ering that the [674R]GPIIb allele is transcribed at normal rates and
this mutation does not preclude a normal receptor responsiveness,
the knowledge of the limiting step(s) in the expression of mutant
heterodimers could eventually help to define a therapeutic target(s).
In secreted proteins, disulfide bonds are important for stabiliza-
tion of the tertiary structure as well as for their assembly into
multimeric complexes.21 Disruption of intrachain disulfide bonds
in GPIIb or GPIIIa produces variable degrees of functional
impairment. Deletion of 106A-111Q, including 107C, disrupts the
107-130 intrachain disulfide bond in GPIIb,22 preventing het-
erodimerization of GPIIb-IIIa.23 Similar results were observed with
the 129S-161S deletion comprising the 130C and 146C residues.24
In GPIIIa, disruption of disulfide bonds by the C374Y and C560F
mutations are associated with type II thrombasthenia,25,26 and
C542R and C457Y substitutions are involved in type I GT.27,28
However, removal of C655 GPIIIa by site-directed mutagenesis
does not affect the GPIIb-IIIa.29 The Cs 674 and 687 in GPIIb are
conserved in all the aIIbb3 integrins of all the species studied so far
(human, dog, pig, rabbit, and rodents). In general, the conservation
of Cs in alpha subunits of integrins runs in parallel to their degree
of homology with GPIIb.30 However, it is worth noting that Cs 674
and 687 are conserved in the alpha subunit of Arg-Gly-Asp
(RGD)–reactive integrins (aIIbb3, a5b1, and avb3) that undergo a
process of cleavage and lack an I domain. In cleaved but
non–RGD-reactive integrins, these Cs are conserved in a7 and a8.
These observations suggest that the 674-687 disulfide bridge in
GPIIb might play an important role in determining the optimal
functional folding. The functional preservation of the [674R]GPIIb-
IIIa complexes supports the idea that disruption of the 674-687
disulfide bond in GPIIb impairs primarily the assembly and/or
intracellular trafficking of heterodimers.
The nascent polypeptide chains would tend to aggregate in the
high-protein–containing intracellular medium unless it was im-
peded by the assistance of molecular chaperones. The chaperones
are important in polypeptide folding, protein assembly, and intracel-
lular translocation.31-33 They bind to hydrophobic domains on the
surface of unfolded polypeptides. As the disulfide bonds are formed
and the protein folding proceeds, most likely, different chaperones
act sequentially until a competent native protein is secreted.34-36
The BiP is a molecular chaperone that targets irreversibly mis-
folded proteins for their degradation in the endoplasmic reticulum
(ER). It is generally accepted that misfolded proteins are never
secreted and remain sequestered in the ER until their degradation is
completed. On these grounds, we found of interest to investigate
the interaction of [674R]GPIIb with BiP and whether this chaper-
one was involved in determining the slow rate of surface exposure
of [674R]GPIIb-IIIa complexes. In agreement with a previous
observation on the mutagenesis of G273 of GPIIb,37 BiP bound
mutated forms of residues 674 or 687 of GPIIb but not to normal
[674C]GPIIb. It should be remarked that, although some of the
introduced mutations improved the exposure of GPIIb-IIIa, none of
them approached values above 50% of the normal rates. Thus, it
seems reasonable to conclude that, at least under our experimental
conditions, a relationship exists between the association of GPIIb
with BiP and reduced surface expression of GPIIb-IIIa. It is
generally accepted that the fate of misfolded proteins is their
complete degradation in the ER. However, in our case, in agree-
ment with an observation made on some mutated forms of the
human chorionic gonadotropin-b subunit,38 at least part of the
mutant [674R]GPIIb protein succeeded in progressing along the
secretory pathway to reach the cell surface. The association of BiP
with heterodimeric complexes supports the relationship between
binding of BiP and the reduced rate of expression of [674R]GPIIb-
IIIa. The tight binding of BiP might impose a major restraint on the
progress of protein complexes along the secretory pathway.
It is worth noting that replacement of 674C for R appeared to
have a more deleterious effect in terms of surface expression than
A, which might be due to constraints imposed by the side-chain on
the BiP binding. It should also be mentioned that, although
mutation of either 674C or 687C produced similar effects, the
additive effect of both mutations suggests their effect may not be
due only to disulfide disruption. A likely interpretation for this
observation is an altered polypeptide conformation independent
from disulfide disruption. Alternatively, the nonmutated C may
engage in disulfide bridging with another C, sufficient to provide a
conformation improving the trafficking or retaining BiP less
efficiently.
Competition between normal and mutant [674R]GPIIb subunits
The heterozygous states for mutations in GPIIb or GPIIIa are
known to contain subnormal amounts of platelet GPIIb-IIIa,
although near normal amounts have also been reported.18 In
principle, the finding of subnormal platelet GPIIb-IIIa content
suggests that transcripts from a single allele are not sufficient to
maintain normal translational rates and, therefore, assembly and
surface exposure. The amount of mutated platelet mRNA-GPIIb in
the heterozygote state for [674R]GPIIb was within the expected
normal range; nevertheless, the amount of platelet GPIIb-IIIa was
approximately 30% of the normal values or, what is the same, about
half of the estimated content, assuming that the contribution of
both, normal (50%) and mutant allele (10%), was additive. The
lack of additivity implies that some type of negative interaction
must be taking place between the mutant and normal subunits.
Under our experimental conditions, coexpression of normal GPIIIa
and progressively increasing ratios of mutant to normal GPIIb led
to progressive inhibition of the surface expression of GPIIb-IIIa in
CHO cells. The physiologic significance of this finding is sup-
ported by the fact that transfection of CHO cells with GPIIIa and
equimolar amounts of normal and mutant GPIIb inhibited the
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exposure of normal GPIIb-IIIa to a similar extent to that observed
in the platelets of the heterozygote individual. The inhibitory effect
of a mutant protein on the wild-type gene product is known as
“dominant-negative” effect.39,40 Dominant-negative effect of mu-
tated proteins seems to be involved in the etiopathogenesis of
several human diseases, such as the thyroid hormone resistance
syndrome41,42 and those originated by mutant p53 tumor suppressor
proteins43 and mutations in the tyrosine kinase domain of the
insulin receptor.44
We have reported competition between other mutated forms of
GPIIb and normal subunits.19 The competition between normal and
mutant subunits may be exerted in different ways, depending for
instance on whether they form homodimers or heterodimers that
may compete for the binding of other subunits or ligands. On the
basis of the strong binding of BiP to monomeric as well as to
heterodimeric mutant [674R]GPIIb-IIIa complexes, we investi-
gated whether the availability of BiP for the assisted folding of
normal subunits could have been limiting. This possibility can be
ruled out since coexpression of BiP enhanced rather than dimin-
ished the inhibitory effects of mutant [674R]GPIIb. The increased
availability of BiP could result in increasing steady-state levels of
[674R]GPIIb-BiP complexes. Thus, the inhibitory effect of overex-
pressing BiP adds further support to the postulate that the mutant
[674R]GPIIb-BiP complex perturbs the secretory pathway of
normal subunits by competing at some limiting step.
To conclude, the lack of the 674-687 disulfide bond in
[674R]GPIIb does not preclude a normal agonist-induced binding
of Fg or of the activation-dependent IgM PAC1 by [674R]GPIIb-
IIIa receptors. BiP forms very stable complexes with either
pro[674R]GPIIb and [674R]GPIIb-IIIa heterodimers but not with
normal GPIIb or GPIIb-IIIa. Mutation analysis of residue 674 of
GPIIb indicates that noncharged or no-polar residues improved the
functional performance of the subunit. However, none of the
analyzed mutants reached the normal values when coexpressed
with normal GPIIIa, and all of them were tightly bound to BiP.
There is a dose-dependent competition between normal and
[674R]GPIIb-IIIa complexes for cell surface expression, and this
effect is enhanced by coexpression of BiP. These observations
suggest that the tight binding of BiP to [674R]GPIIb may be related
to the slow rate of progression of [674R]GPIIb-IIIa along the
secretory pathway and the competition between normal and mutant
heterodimers.
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